Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment Kumar Jeetendra | September 26, 2023 Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec®100/6 (beclometasone 100µg / for moterol 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. Luforbec®100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where …
